Related Experiment Video
Updated: Jul 29, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Recent advances in the development of dual ALK/ROS1 inhibitors for non-small cell lung cancer therapy
Yingxue Li1, Yanna Lv1, Cheng Zhang1
1Weifang Medical University, No.7166 Baotong Road, Weifang, 261053, PR China.
Abstract:
As a member of the insulin-receptor superfamily, ALK plays an important role in regulating the growth, proliferation, and survival of cells. ROS1 is highly homologous with ALK, and can also regulate normal physiological activities of cells. The overexpression of both is closely related to the development and metastasis of tumors. Therefore, ALK and ROS1 may serve as important therapeutic targets in non-small cell lung cancer (NSCLC). Clinically, many ALK inhibitors have shown powerful therapeutic efficacy in ALK and ROS1-positive NSCLC patients. However, after some time, patients inevitably develop drug resistance, leading to treatment failure. There are no significant drug breakthroughs in solving the problem of drug-resistant mutations. In this review, we summarize the chemical structural features of several novel dual ALK/ROS1 inhibitors, their inhibitory effect on ALK and ROS1 kinases, and future treatment strategies for patients with ALK and ROS1 inhibitor-resistant mutations.
Insights
Novel dual ALK/ROS1 inhibitors show promise for non-small cell lung cancer (NSCLC) patients who develop resistance to existing therapies. This review explores new inhibitors targeting drug-resistant mutations in ALK and ROS1 kinases.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Anaplastic Lymphoma Kinase (ALK) and ROS1 are critical in cell growth and survival.
- Their overexpression is linked to non-small cell lung cancer (NSCLC) development and metastasis.
- Current ALK inhibitors are effective but face challenges with acquired drug resistance.
Purpose of the Study:
- To review novel dual ALK/ROS1 inhibitors.
- To analyze their chemical structures and inhibitory effects.
- To discuss future strategies for overcoming resistance mutations.
Main Methods:
- Literature review of recent studies on ALK and ROS1 inhibitors.
- Analysis of chemical structures and kinase inhibition data.
- Synthesis of findings to propose treatment strategies.
Main Results:
- Several novel dual ALK/ROS1 inhibitors exhibit potent activity.
- These inhibitors demonstrate efficacy against resistant ALK and ROS1 mutations.
- Chemical structures are correlated with inhibitory potency and resistance profiles.
Conclusions:
- Dual ALK/ROS1 inhibitors represent a promising therapeutic avenue for NSCLC.
- Targeting resistant mutations is crucial for long-term treatment success.
- Further research into novel inhibitors is warranted to address treatment failure.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
